Amstelveen
Amstelveen
Amstelveen, North Holland, Netherlands5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Microcirculation, Dialysis Modality and Sequestered Salt | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic kidney disease, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Recruiting | Not applicable | 2026-09-11 | NCT06327750 | |
| Loose Seton Prior to Surgery for Single-tract Cryptoglandular Fistula vs no Seton | Cryptoglandular Perianal Fistula | Recruiting | Not applicable | 2026-09-08 | NCT07807319 | |
| Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Active, not recruiting | Phase 3 | 2026-08-25 | NCT05030428 | |
| Hybrid Dialectical Behavior Therapy for Veterans to Further Reduce Emotion Regulation Problems and Trauma Symptoms | Chemically-Induced Disorders, Stress Disorders, Traumatic, acute stress disorder, post-traumatic stress disorder, psychiatric disorder, substance abuse, substance-related disorder | Recruiting | Not applicable | 2026-06-17 | NCT07652645 | |
| Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Active, not recruiting | Phase 3 | 2026-04-23 | NCT06008756 |